Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „NOTE“
Suchtreffer
Begriffe & Kennungen
Moventig · 4.8 · Skin and Hyperhidrosis subcutaneous tissue disorders Note: Selection of ADRs and their frequencies based on th
Eintrag öffnenMukokutanes Lymphknotensyndrom
Eintrag öffnenMvasi · 4.8 · When events were noted as both all grade and grade 3-5 adverse drug reactions in clinical trials, the highest
Eintrag öffnenNanotechnologie
Eintrag öffnenNexavar · 4.5 · Doxorubicin/Irinotecan
Eintrag öffnenNinlaro · 4.8 · Unless otherwise noted, the data presented below is the pooled safety data from the pivotal, Phase 3, global C
Eintrag öffnenNorvir · 4.8 · Events noted as having a frequency not known were identified via post-marketing surveillance
Eintrag öffnenNorvir · 4.8 · Events noted as having frequency not known were identified via post-marketing surveillance.
Eintrag öffnenNuceiva · 4.8 · Note: Of the 1,659 subjects treated with NUCEIVA, rare events occurred in 1 subject only. Uncommon events occu
Eintrag öffnenOligospermie
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.3 · History of severe hypersensitivity to irinotecan or to any of the excipients listed in section 6.1.
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.5 · Antineoplastic agents (including flucytosine as a prodrug for 5-fluorouracil) Adverse effects of irinotecan, s
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.5 · Strong CYP3A4 inducers Patients receiving concomitant non-liposomal irinotecan and CYP3A4 enzyme-inducing anti
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.5 · Strong CYP3A4 inhibitors and UGT1A1 inhibitors Patients receiving concomitant non-liposomal irinotecan and ket
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.8 · In clinical studies of non-liposomal irinotecan administered on a weekly dosage schedule, patients with modest
Eintrag öffnenOrganisatoren, embryonale
Eintrag öffnenOrganotechnetiumverbindungen
Eintrag öffnenOzempic · 4.8 · 7 see footnote in Table 1) are based on a pool of the phase 3a trials excluding the cardiovascular outcomes tr
Eintrag öffnenPoxviridaeinfektionen
Eintrag öffnenPramipexol
Eintrag öffnen